The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries. 

The study's authors communicated with ChatGPT-4 in both English and Japanese, noting that it appeared to struggle more with the complexities of the Japanese language. 

Medical facilities and distributors have been advised to immediately discontinue the use of these devices due to a significant labeling issue. 

Lawrence Faucette, the second patient to ever receive a genetically modified pig heart, died on Oct. 30. “He can never be forgotten," his wife said in a statement. 

A cardiologist-led think tank tracked data from more than 1 million procedures, exploring the clinical and economic impacts of implanting low-value coronary stents. 

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.